Esperion Therapeutics
Data Breaches, Cyber Attacks and Security Report

https://esperion.com  ᛫  Biotech & Pharmaceuticals
Last updated December 10, 2019

About Esperion Therapeutics

Company Overview

Esperion Therapeutics, Inc. is a public, American pharmaceutical company focused on the development of a first-in-class, orally available, small molecule designed to significantly lower elevated levels of LDL-C - with the reduced potential for muscle-related side effects associated with statin use.

Valuation

$1,938,391,100

Employees

CEO

Tim Mayleben

Location

Ann Arbor, MI, United States.

Data Breaches and Security News

Esperion Therapeutics Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Esperion Therapeutics is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Esperion Therapeutics

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Esperion Therapeutics's security performance with other companies